GMED Stock Analysis — Globus Medical
Sector: Healthcare
AI Verdict
GMED looks cheap for the growth you're getting, and its robotics-driven moat gives the earnings forecast more credibility than most in the sector.
Competitive Moat
Globus Medical specializes in musculoskeletal implants and robotic surgery systems, with a defensible moat built around proprietary surgical robotics and a broad spine device portfolio. The integration of hardware, software, and surgeon training creates switching costs for hospitals and clinics.
Summary
GMED is drawing attention for its 18.3% expected EPS growth and a forward P/E of 16.3x, both outpacing typical healthcare peers.
Where It Stands
Shares trade at 16.3x next year's earnings versus a healthcare sector median of 22x, while delivering 18.3% forward EPS growth and a 23.5% trailing revenue increase.
Key Metrics
- Trailing P/E: 19.2x
- Forward P/E: 16.3x
- PEG Ratio: 1.05
- Earnings Growth: +0.2%
- Revenue Growth: +0.2%
- 52-Week High: $101.40
- 52-Week Low: $51.79
Analyst Consensus
16 Buy · 6 Hold · 0 Sell (22 analysts)
Bull Case
With a forward P/E of 16.3x and 18.3% EPS growth expected, you're getting growth at a discount to the sector median multiple.
Bear Case
If the P/E multiple snaps back to the sector median of 22x, the upside is capped unless GMED sustains or accelerates its 18.3% EPS growth pace.
Catalyst to Watch
Watch for new product launches or FDA approvals in robotic surgery that could accelerate adoption and justify the current growth premium.